Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: Implications for monitoring of neoplastic disease

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7444-7451

  Terrin, Liliana ^a,b   Rampazzo, Enrica ^a,b   Pucciarelli, Salvatore ^a   Agostini, Marco ^a   Bertorelle, Roberta ^b   Esposito, Giovanni ^b   DelBianco, Paola ^b   Nitti, Donato ^a   De Rossi, Anita ^a,b,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Department of Oncology and Surgical Sciences   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER; BIOLOGICAL MARKER; TELOMERASE; TERT PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TUMOR GROWTH; BIOSYNTHESIS; COLORECTAL TUMOR; DISEASE COURSE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; TELOMERASE;

EID: 58149352913     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0478     Document Type: Article

References (44)

1. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
2. Esposito G, Pucciarelli S, Alaggio R, et al. 27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-8.
3. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767-72.
4. Hsieh JS, Lin SR, Chang MY, et al. APC, K-ras, and p53 genemutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 2005;71:336-43.
5. Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res 2007;13:2406-13.
6. Khair G, Monson JR, Greenman J. Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. Dis Colon Rectum 2007;50:1188-203.
7. El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2002;50:564-73.
8. Tsui NB, Ng EK, LOYM. Stability of endogenous and added RNA in blood specimens, serum and plasma. Clin Chem 2002;48:1647-53.
9. Cerkovnik P, Perhavec A, Zgajnar J, Novakovic S. Optimization of an RNA isolation procedure from plasma samples. Int J Mol Med 2007;20:293-300.
10. Collado M, Garcia V, Garcia JM, et al. Genomic profiling of circulating plasma RNA for the analysis of Cancer. Clin Chem 2007;53:1860-3.
11. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
12. Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004;340:1-10.
13. Kelland L. Trageting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007;13:4960-3.
14. Niiyama H, Mizumoto K, Sato N, et al. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001;96:1895-900.
15. Naito Y, Takagi T, Handa O, et al. Telomerase activity and expression of telomerase RNA component and catalytic subunits in precancerous and cancerous colorectal lesions. Tumour Biol 2001;22:374-82.
16. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 2002;95:2103-11.
17. Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol 2003;15:75-80.
18. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004;22:807-14.
19. Boldrini L, Faviana P, Gisfredi S, et al. Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncol Rep 2004;11:395-400.
20. Garcia-Aranda C, de Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006;106:541-51.
21. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000;6:2696-701.
22. Ghori A, Usselmann B, Ferryman S, Morris A, Fraser I. Telomerase expression of malignant epithelial cells correlates with Dukes' stage in colorectal cancer. Colorectal Dis 2002;4:441-6.
23. Maláska J, Kunická Z, Borskẙ M, et al. Telomerase as a diagnostic and predictive marker in colorectal carcinoma. Neoplasma 2004;51:90-6.
24. Lledo SM, Garcia-Granero E, Dasi F, et al. Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis 2004;6:236-42.
25. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998;58:4168-72.
26. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer 2001;91:644-9.
27. Zaffaroni N, Villa R, Pastorino U, et al. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres. Clin Cancer Res 2005;11:2832-9.
28. Greene FL, Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia: Springer; 2002.
29. Terrin L, Dolcetti R, Corradini I, et al. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis. Int J Cancer 2007;121:576-87.
30. Terrin L, Trentin L, Degan M, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. Leukemia 2007;21:965-72.
31. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 2005;85:154-9.
32. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-8.
33. Ballon G, Ometto L, Righetti E, et al. Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes. J Infect Dis 2001;183:417-24.
34. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
35. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet1998;19:182-6.
36. Hess JL, Highsmith WE, Jr. Telomerase detection in body fluids. Clin Chem 2002;48:18-24.
37. Murillo-Ortiz B, Astudillo-De la Vega H, Castillo-Medina S, Malacara JM, Benitez-Bribiesca L. Telomerase activity, estrogen receptors (α,β), Bcl-2 expression in human breast cancer and treatment response. BMC Cancer 2006;6:206.
38. Fakhoury J, Nimmo GA, Autexier C. Harnessing telomerase in cancer therapeutics. Anticancer Agents Med Chem 2007;7:475-83.
39. Domont J, Pawlik TM, Boige V, et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 2005;23:3086-93.
40. Chen XQ, Bonnefoi H, Pelte MF, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-6.
41. Miura N, Maeda Y, Kanbe T, et al. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 2005;11:3205-9.
42. Pelosi G, Schianchi E, Dell'Orto P, et al. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch 2006;448:7-15.
43. Tani N, Ichikawa D, Ikoma D, et al. Circulating cell-free mRNA in plasma as a tumor marker for patients with primary and recurrent gastric cancer. Anticancer Res 2007;27:1207-12.
44. Dasi F, Martinez-Rodes P, March JA, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann N Y Acad Sci 2006;1075:204-10.